<DOC>
	<DOCNO>NCT02966782</DOCNO>
	<brief_summary>This Phase 1b , dose-ranging , open-label , multicenter study design evaluate safety , pharmacokinetics , efficacy venetoclax single-agent combination azacitidine participant higher-risk Myelodysplastic Syndromes ( MDS ) Hypomethylating Agent ( HMA ) -Failure .</brief_summary>
	<brief_title>A Study Evaluating Venetoclax Combination With Azacitidine Compared With Azacitidine Alone Participants With Higher-Risk Myelodysplastic Syndromes ( MDS ) After Hypomethylating Agent-Failure</brief_title>
	<detailed_description>Interventional study design - primary objective : Assess safety pharmacokinetics venetoclax single-agent combination azacitidine .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Participant must document diagnosis classification Myelodysplastic Syndromes ( MDS ) application International Prognostic Scoring System ( IPSS ) Higher Risk ( HR ) MDS time first diagnosis IPSS risk category Int2 High ( IPSS overall score great equal 1.5 ) . Participants must presence great equal 5 % le 30 % bone marrow blast per bone marrow biopsy/aspirate screening . Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 . Participant must failure prior therapy Hypomethylating Agent ( HMA ) ( azacitidine decitabine ) firstline MDS treatment . Participant must adequate hematologic , renal , hepatic function . Participant lowerrisk MDS IPSS risk category Low Int1 ( overall IPSS score &lt; 1.5 ) time first diagnosis . Participant therapyrelated MDS ( tMDS ) . Participant MDS evolve preexist myeloproliferative neoplasm ( MPN ) . Participant MDS/MPN include chronic myelomonocytic leukemia ( CMML ) , atypical chronic myelogenous leukemia ( CML ) , juvenile myelomonocytic leukemia ( JMML ) unclassifiable MDS/MPN . Participant receive 1 prior therapy . Participant receive therapy azacitidine decitabine treatment MDS . Participant receive prior therapy BH3 mimetic . Participant receive hematopoietic growth factor , agent intend improve blood count ( e.g. , erythropoietin , eltrombopag ) , corticosteroid within 14 day prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Azacitidine</keyword>
	<keyword>Venetoclax</keyword>
	<keyword>Higher-Risk ( HR ) Myelodysplastic Syndromes ( MDS )</keyword>
	<keyword>International Prognostic Scoring System ( IPSS )</keyword>
	<keyword>Hypomethylating Agent-Failure ( HMA )</keyword>
</DOC>